Chardan Capital Has Strong Forecast for NTLA FY2025 Earnings

Key Points

• Chardan Capital has raised its FY2025 earnings estimate for Intellia Therapeutics to (\$4.01) per share from a previous estimate of (\$4.25), maintaining a "Buy" rating with a target price of \$60.00.
• Intellia's most recent quarterly earnings showed an EPS of (\$0.99), beating expectations, with significant revenue growth of 104.3% year-over-year, totaling \$14.25 million.
• Institutional investors hold approximately 88.77% of Intellia's stock, indicating substantial interest from large investment firms, while insider selling has also occurred recently.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at Chardan Capital increased their FY2025 earnings estimates for shares of Intellia Therapeutics in a research report issued on Monday, August 11th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($4.01) per share for the year, up from their previous estimate of ($4.25). Chardan Capital currently has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share.

Several other brokerages also recently commented on NTLA. Wells Fargo & Company reiterated an "overweight" rating and issued a $45.00 target price (down previously from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Wedbush reiterated a "neutral" rating and issued a $7.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. Citigroup dropped their price objective on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective on the stock in a report on Monday, April 21st. Finally, Royal Bank Of Canada dropped their price objective on shares of Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.05.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $10.96 on Thursday. The company has a market capitalization of $1.18 billion, a PE ratio of -2.42 and a beta of 2.31. Intellia Therapeutics has a one year low of $5.90 and a one year high of $24.16. The company's fifty day moving average price is $10.75 and its 200 day moving average price is $9.50.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The business had revenue of $14.25 million during the quarter, compared to analyst estimates of $12.26 million. During the same quarter in the previous year, the business earned ($1.52) EPS. Intellia Therapeutics's quarterly revenue was up 104.3% compared to the same quarter last year.

Hedge Funds Weigh In On Intellia Therapeutics

A number of large investors have recently modified their holdings of NTLA. Voloridge Investment Management LLC lifted its position in shares of Intellia Therapeutics by 226.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock worth $17,805,000 after purchasing an additional 1,059,751 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in Intellia Therapeutics by 94.5% in the fourth quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock valued at $23,300,000 after buying an additional 970,700 shares during the period. Two Sigma Investments LP lifted its holdings in Intellia Therapeutics by 88.1% in the fourth quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock valued at $21,498,000 after buying an additional 863,363 shares during the period. Baker BROS. Advisors LP acquired a new position in Intellia Therapeutics in the fourth quarter valued at approximately $7,510,000. Finally, Vanguard Group Inc. lifted its holdings in Intellia Therapeutics by 5.5% in the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock valued at $76,447,000 after buying an additional 561,978 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the transaction, the executive vice president directly owned 106,062 shares in the company, valued at $1,486,989.24. The trade was a 6.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 12,534 shares of company stock valued at $153,837 in the last quarter. 3.10% of the stock is owned by insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.